CN Bio launches PhysioMimix® Core, a universal microfluidic platform

14 October 2025

Cambridge-based CN Bio, a leading provider of organ-on-a-chip solutions, today announced the launch of its PhysioMimix® Core microphysiological system. The idea behind this product development was to merge the existing PhysioMimix single-organ, multi-organ and higher throughput systems into one intuitive, adaptable and universal platform so that researchers could use it with maximum flexibility.

Compact and scalable, this latest CN Bio's platform further supports human-relevant disease modelling and mechanisms elucidation, drug discovery and testing, as well as predictive toxicology and ADME.

Apart from ease of use, simple installation and seamless integration into existing workflows, the competitive advantages of PhysioMimix® Core include open architecture for facilitated access to cell culture and relatively large-scale recoverable microtissue so that histology and omics analysis can be run in parallel on the same tissue. This system provides single-organ and multi-organ capabilities, supporting the investigation of both organ-specific properties and interactions between organs. With each plate incorporating 6-48 chips and each controller running up to six multi-chip plates at a time, PhysioMimix offers its users one of the highest throughput capabilities in class. As to avoid non-specific binding of drugs to PDMS, CN Bio had opted for the use of cyclic olefin copolymer (COC).

Dr Paul Brooks, CEO, CN Bio, commented: “2025 has been an exciting year for the OOC sector, with legislative changes demonstrating a distinct shift towards new approach methodologies (NAMs) and allowing drug developers the flexibility to choose the most effective tools to advance their research,” He added: “PhysioMimix Core directly addresses the gap in the market for a unified OOC system that is adaptable across the entire drug discovery and development pipeline. We work closely with regulators to anticipate the direction of the field, and this launch represents our focus on streamlining adoption and ensuring our customers stay ahead of that curve.”

Sung Lee, Director, CN Bio, added: “PhysioMimix Core is a bold next step for the brand. By combining the strengths of all our existing Systems into one intuitive platform, we’ve created a solution that delivers physiological precision with ease-of-use. We appreciate the field is evolving rapidly, our goal is to empower researchers with a future-proof system that unlocks deeper insights into human biology.  With PhysioMimix Core, scientists gain unprecedented control and scalability, enabling them to push boundaries and accelerate breakthroughs across the drug development pipeline.”